Long-term bone mineral density response to enzyme replacement therapy in a retrospective pediatric cohort of Gaucher patients

[1]  P. Kaplan,et al.  Osteopenia in Gaucher disease develops early in life: response to imiglucerase enzyme therapy in children, adolescents and adults. , 2011, Blood cells, molecules & diseases.

[2]  P. Stein,et al.  Osseous Manifestations of Adult Gaucher Disease in the Era of Enzyme Replacement Therapy , 2011, Medicine.

[3]  R. Eastell,et al.  Lumbar spine peak bone mass and bone turnover in men and women: a longitudinal study , 2009, Osteoporosis International.

[4]  P. Kaplan,et al.  Eight-Year Clinical Outcomes of Long-Term Enzyme Replacement Therapy for 884 Children With Gaucher Disease Type 1 , 2008, Pediatrics.

[5]  S. Silverman,et al.  Special report on the 2007 adult and pediatric Position Development Conferences of the International Society for Clinical Densitometry , 2008, Osteoporosis International.

[6]  P. Kaplan,et al.  Improvement of bone disease by imiglucerase (Cerezyme) therapy in patients with skeletal manifestations of type 1 Gaucher disease: results of a 48-month longitudinal cohort study , 2008, Clinical genetics.

[7]  P. Kaplan,et al.  Recommendations for the assessment and monitoring of skeletal manifestations in children with Gaucher disease , 2008, Skeletal Radiology.

[8]  P. Mistry,et al.  Enzyme replacement therapy and bony changes in Egyptian paediatric Gaucher disease patients , 2006, Journal of Inherited Metabolic Disease.

[9]  L. Ronfani,et al.  Gaucher disease and bone: Laboratory and skeletal mineral density variations during a long period of enzyme replacement therapy , 2005, Journal of Inherited Metabolic Disease.

[10]  P. Kaplan,et al.  Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry. , 2002, The American journal of medicine.

[11]  D. Häussinger,et al.  Correlation of bone marrow response with hematological, biochemical, and visceral responses to enzyme replacement therapy of nonneuronopathic (type 1) Gaucher disease in 30 adult patients. , 2002, Blood cells, molecules & diseases.

[12]  C. Scriver,et al.  The Metabolic and Molecular Bases of Inherited Disease, 8th Edition 2001 , 2001, Journal of Inherited Metabolic Disease.

[13]  P. Kaplan,et al.  The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease. , 2000, Archives of internal medicine.

[14]  R. Desnick,et al.  Bone density in type 1 gaucher disease , 1996, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[15]  O Manor,et al.  Acceleration of retarded growth in children with Gaucher disease after treatment with alglucerase. , 1996, The Journal of pediatrics.

[16]  J. Dambrosia,et al.  Enzyme replacement therapy for Gaucher disease: skeletal responses to macrophage-targeted glucocerebrosidase. , 1995, Pediatrics.

[17]  A. Saven,et al.  Gaucher Disease: Clinical, Laboratory, Radiologic, and Genetic Features of 53 Patients , 1992 .

[18]  S. Teitelbaum,et al.  Skeletal Complications of Gaucher Disease , 1985, Medicine.

[19]  B. Bembi,et al.  Bone complications in children with Gaucher disease. , 2002, The British journal of radiology.

[20]  R. Van Tiggelen,et al.  Gaucher disease , 2019, Haematology.